Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Ozet, Ahmet; Ünsal, Oktay; Yazıcı, Ozan; Ozdemir, Nuriye

doi:10.5455/annalsmedres.2023.07.160

Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Oktay ÜNSAL, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Ozan YAZICI, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Nuriye OZDEMİR, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Ahmet OZET (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, Ankara, Türkiye)

Annals of Medical Research

6 2

Yıl: 2023 Cilt: 30 Sayı: 8 Sayfa Aralığı: 965 - 969 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2023.07.160 İndeks Tarihi: 01-11-2023

Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma

Öz:

Aim: This study aimed to analyse the clinical characteristics, effectiveness and safety of nivolumab monotherapy in patients aged≥ 65 years with metastatic melanoma. Materials and Methods: This study involved patients aged ≥65 years who were diagnosed with metastatic cutaneous or mucosal melanoma. Patients with BRAF wild type, ECOG performance status 0-1, and who had previously received one line of chemotherapy were included, irrespective of PD-L1 expression. The study analyzed PFS, OS, and adverse event profiles. Results: Twenty-one patients, with a median age of 70, were analysed in the study. The median PFS for nivolumab as second-line therapy in elderly patients was 3.5 months (95% CI, 1.5 to 5.6 months), while the median OS was 14.5 months (95% CI, 10.3 to 18.6 months). The most common grade 1-2 adverse events were anemia (66.7%) and serum creatinine increase (23.8%). Additionally, the rate of grade 3-4 adverse events due to all causes was 28.6%. There was no grade 5 adverse event. Conclusion: Nivolumab is effective and safe as second-line therapy in patients aged ≥65 years with metastatic melanoma. It is a tolerable and effective treatment choice for elderly patients who cannot received nivolumab in first line therapy.

Anahtar Kelime: Nivolumab Elderly patients Malign melanoma Anti pd-1

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013; 20: 3961-8.
2. Cybulska-Stopa B, Ługowska I, Jagodzńska-Mucha P, et al. Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 2019;36(5):566-71. doi:10.5114/ada.2018.79940.
3. Iacono D, Vitale MG, Basile D, et al. Immunotherapy for older patients with melanoma: From darkness to light? Pigment Cell Melanoma Res. 2021; 34: 550–63. https://doi.org/10.1111/pcmr.12917.
4. Pera A, Campos C, López N, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas 2015; 82: 50-5.
5. Weiss SA, Han J, Darvishian F, et al. Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. J Transl Med 2016; 14: 299.
6. Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature medicine 2021; 27(2): 256-63.
7. Xuan-zhang H, Peng G, Yong-xi S, et al. Efficacy of immune checkpoint inhibitors and age in cancer patients. Immunotherapy 2020; 12(8): 587-603.
8. Russo AE, Ferraù F, Antonelli G, et al. Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Rev Anticancer Ther. 2015 Jan;15(1):101-8. doi: 10.1586/ 14737140.2015.961426.
9. Freeman M, Weber J. Subanalysis of the Safety and Efficacy of Nivolumab in Elderly Patients with Metastatic Melanoma. Journal for ImmunoTherapy of Cancer 2015, 3(2):133.
10. Orloff M. Melanoma Immunotherapy in the Elderly. Curr Oncol Rep. 2018; 20: 20. https://doi.org/10.1007/s11912-018-0656-3.
11. Deeks ED. Nivolumab: A Review of Its Use in Patients with Malignant Melanoma. Drugs 2014; 74: 1233–9. https://doi.org/10.1007/s40265-014-0234-4.
12. Uhara H, Tsuchida T, Kiyohara Y, et al. Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post-marketing surveillance. J Dermatol. 2022 Sep;49(9):862-71. doi: 10.1111/1346-8138.16432.
13. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
14. Paly V, Colby C, Guilloteau I,et al. Predictors of utility over time among patients with treatment-naïve advanced melanoma from the phase 3 Checkmate 066 trial [abstract PCN247]. Value Health 2015;18:A474.
15. Robert C, Long GV, Brady B, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J. Clin. Oncol. 2020; 38: 3937–46.
16. Age does matter in adolescents and young adults versus older adults with advanced melanoma; A national cohort study comparing tumor characteristics, treatment pattern, toxicity and response. Cancers. Jul 27 2020; 12(8): 1-15.
17. De Luca R, Meraviglia S, Blasi L, et al. Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients. Current Oncology. 2020; 27(2):75-80. https://doi.org/10.3747/co.27.5293.
18. Kim J, Singh H, Ayalew K, et al. Use of pro measures to inform tolerability in oncology trials: implications for clinical review, ind safety reporting, and clinical site inspections. Clin Cancer Res 2018;24:1780–4.
19. Monestier S, Dalle S, Mortier L et al. Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. Int. J. Cancer 2021; 148, 2789–98.
20. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375–84. doi: 10.1016/S1470-2045(15)70076-8.
21. Larkin J, Minor D, D’Angelo S, et al. Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J. Clin. Oncol. 2018;36:383–90. doi: 10.1200/JCO.2016.71.8023.
22. Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014;63:449-58.
23. Bocquet-Tremoureux S, Scharbarg E, Nguyen J-M, et al. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. Eur J Dermatol 2019;29:315–21. 10.1684/ejd.2019.3558.
24. Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wildtype advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1:433-40.
25. Afrăsânie V-A, Alexa-Stratulat T, Gafton B, et al. Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors. Cancers. 2023; 15(4):1265. https://doi.org/10.3390/cancers15041265.
26. Singh H, Kim G, Maher VE, et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J. Clin. Oncol. 2016; 34 (15):10010.
27. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am. J. Kidney Dis. 2016; 68, 287–91.

APA	Ünsal O, Yazıcı O, Ozdemir N, Ozet A (2023). Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. , 965 - 969. 10.5455/annalsmedres.2023.07.160
Chicago	Ünsal Oktay,Yazıcı Ozan,Ozdemir Nuriye,Ozet Ahmet Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. (2023): 965 - 969. 10.5455/annalsmedres.2023.07.160
MLA	Ünsal Oktay,Yazıcı Ozan,Ozdemir Nuriye,Ozet Ahmet Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. , 2023, ss.965 - 969. 10.5455/annalsmedres.2023.07.160
AMA	Ünsal O,Yazıcı O,Ozdemir N,Ozet A Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. . 2023; 965 - 969. 10.5455/annalsmedres.2023.07.160
Vancouver	Ünsal O,Yazıcı O,Ozdemir N,Ozet A Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. . 2023; 965 - 969. 10.5455/annalsmedres.2023.07.160
IEEE	Ünsal O,Yazıcı O,Ozdemir N,Ozet A "Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma." , ss.965 - 969, 2023. 10.5455/annalsmedres.2023.07.160
ISNAD	Ünsal, Oktay vd. "Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma". (2023), 965-969. https://doi.org/10.5455/annalsmedres.2023.07.160

APA	Ünsal O, Yazıcı O, Ozdemir N, Ozet A (2023). Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research, 30(8), 965 - 969. 10.5455/annalsmedres.2023.07.160
Chicago	Ünsal Oktay,Yazıcı Ozan,Ozdemir Nuriye,Ozet Ahmet Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research 30, no.8 (2023): 965 - 969. 10.5455/annalsmedres.2023.07.160
MLA	Ünsal Oktay,Yazıcı Ozan,Ozdemir Nuriye,Ozet Ahmet Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research, vol.30, no.8, 2023, ss.965 - 969. 10.5455/annalsmedres.2023.07.160
AMA	Ünsal O,Yazıcı O,Ozdemir N,Ozet A Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research. 2023; 30(8): 965 - 969. 10.5455/annalsmedres.2023.07.160
Vancouver	Ünsal O,Yazıcı O,Ozdemir N,Ozet A Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma. Annals of Medical Research. 2023; 30(8): 965 - 969. 10.5455/annalsmedres.2023.07.160
IEEE	Ünsal O,Yazıcı O,Ozdemir N,Ozet A "Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma." Annals of Medical Research, 30, ss.965 - 969, 2023. 10.5455/annalsmedres.2023.07.160
ISNAD	Ünsal, Oktay vd. "Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma". Annals of Medical Research 30/8 (2023), 965-969. https://doi.org/10.5455/annalsmedres.2023.07.160